New pill targets Hard-to-Treat cancers in early human test

NCT ID NCT06264921

Terminated Disease control Sponsor: NiKang Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an experimental oral drug called NKT3447 in 23 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NKT3447 (an oral CDK2 inhibitor)
What this could lead to: If it works, this could point toward a new treatment option for certain advanced solid tumors, especially ovarian cancer with CCNE1 amplification.
What could go wrong: This was a very early (Phase 1) trial with only 23 participants, and it was terminated early. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrial disorder endometrium neoplasm estrogen-receptor negative breast cancer gastric cancer gastric carcinoma gastric neoplasm gastroesophageal junction adenocarcinoma Her2-receptor negative breast cancer hormone receptor-positive breast cancer metastatic neoplasm neoplasm Neoplasm Metastasis ovarian cancer ovarian carcinoma ovarian neoplasm progesterone-receptor positive breast cancer small cell lung carcinoma triple-negative breast carcinoma uterine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED ENDOMETRIAL CARCINOMA ADVANCED GASTRIC CARCINOMA ADVANCED OVARIAN CARCINOMA ADVANCED SOLID TUMOR CCNE1 AMPLIFICATION ENDOMETRIAL CANCER ENDOMETRIAL DISEASES ENDOMETRIAL NEOPLASMS GASTRIC CANCER HORMONE RECEPTOR NEGATIVE BREAST CARCINOMA HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST METASTATIC ENDOMETRIAL CANCER METASTATIC ENDOMETRIAL CARCINOMA METASTATIC GASTRIC CANCER METASTATIC GASTRIC CARCINOMA METASTATIC OVARIAN CARCINOMA METASTATIC TUMOR OVARIAN CANCER OVARIAN CARCINOMA OVARIAN NEOPLASMS PLATINUM-REFRACTORY OVARIAN CARCINOMA PLATINUM-RESISTANT OVARIAN CANCER PROGESTERONE-RECEPTOR-POSITIVE BREAST CANCER SMALL CELL LUNG CANCER SMALL CELL LUNG CARCINOMA SOLID TUMOR SOLID TUMOR, ADULT TRIPLE NEGATIVE BREAST CANCER TRIPLE NEGATIVE BREAST NEOPLASMS

Contacts and locations

Locations

AdventHealth Cancer Institute

Celebration, Florida, 34747, United States
Augusta University Georgia Cancer Center

Augusta, Georgia, 30909, United States
Norton Cancer Institute - Broadway

Louisville, Kentucky, 40202, United States
START Mountain Region

West Valley City, Utah, 84119, United States
Sarah Cannon Research Institute at HealthONE

Denver, Colorado, 80218, United States
Texas Oncology-Austin Midtown NEXT Oncology

Austin, Texas, 78758, United States
The Gabrail Pharmacology Phase 1 Research Center

Canton, Ohio, 44718, United States
University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.